Colgate-Palmolive Officer Receives Annual Equity Award Grant
COLGATE PALMOLIVE CO
Subscribe to track CL
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
### Insider Transaction: Colgate-Palmolive Co ($CL)
**Insider:** Tsourapas Panagiotis (COO, CD, EMEA, APac, Skin)
**Type:** Grant / Award (Code A)
**Date:** September 16, 2026
- **Shares Granted (RSUs):** 4,597 shares @ $0.00
- **Stock Options Granted:** 31,814 options ($87.02 strike, exp. 2036-09-16)
- **Direct Ownership Post-Transaction:** 11,447 shares
- **Indirect Holdings:** 69,520 shares (64,901 via Trust, 4,619 via 401(k))
- **Significance:** Low (Routine incentive compensation grant)
Comprehensive Analysis
Executive Summary
On September 16, 2026, Panagiotis Tsourapas, Chief Operating Officer for CD, EMEA, APac, and Skin at Colgate-Palmolive Co ($CL), received an annual incentive compensation award comprising restricted stock units (RSUs) and stock options. Because this filing reflects an ordinary equity grant under the issuer's incentive compensation plan rather than an open-market purchase or sale, its trading significance is Low.
Transaction Highlights
- Restricted Stock Units: Acquired 4,597 shares of Common Stock at $0.00 per share (Transaction Code A). These vest in three equal annual installments over the next three years.
- Stock Options: Granted 31,814 stock options with an exercise price of $87.02 per share, expiring September 16, 2036. The options vest in one-third annual increments starting on the first anniversary of the grant.
- Direct Holdings: Directly held shares increased from 6,850 to 11,447 following the RSU grant.
- Indirect Holdings: The reporting owner also indirectly holds 64,901 shares via a trust and 4,619 shares via the issuer's 401(k) plan trustee.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.